+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study

Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study

Climacteric 6(3): 211-220

To assess the efficacy and tolerability of intravaginal rings (IVRs) delivering estradiol. This was a dose-escalating, continuous-dosing, pilot study. Sixteen women post surgical menopause were recruited at a hospital-based menopause clinic. Over 20 weeks, each patient had IVR devices releasing 50, 75, 100, 150 and 200 mug/day of estradiol inserted consecutively at 4-weekly intervals. Climacteric symptoms were assessed, and levels of serum estradiol, lipoproteins and biochemical indices of bone turnover were estimated prior to insertion of the first IVR and at each monthly visit, when the IVR was changed to one of a higher dose. The susceptibility of low-density lipoprotein (LDL) to oxidation was assessed at 0, 12 and 20 weeks. Twelve women completed the study. The rings were well tolerated and serum estradiol levels increased in parallel with each increasing dose. Vasomotor and psychological symptoms and loss of libido were reduced by 76% (p < 0.001), 44% (p < 0.001) and 44% (p < 0.05), respectively, by the end of the study. There were no significant changes in levels of serum lipoproteins, although the ratio of LDL cholesterol to high-density lipoprotein cholesterol decreased by 7.2% (p = 0.01) after 20 weeks. The susceptibility of LDL to oxidation did not change. Urinary excretion of both calcium and deoxypyridinoline cross-links decreased significantly (p < 0.001), indicating a reduction in bone resorption. The rings were effective in controlling climacteric symptoms and had beneficial effects on bone metabolism, but no significant effects on lipoprotein levels or the susceptibility of LDL to oxidation.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048918267

Download citation: RISBibTeXText

PMID: 14567769

DOI: 10.1080/cmt.

Related references

Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. European Journal of Clinical Investigation 21(6): 601-607, 1991

A novel oestradiol-desogestrel preparation for hormone replacement therapy: Effects on hormones, lipids, bone, climacteric symptoms and endometrium. Maturitas 16(1): 1-12, 1993

Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecological Endocrinology 17(3): 247-254, 2003

A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausal women with climacteric symptoms. Maturitas 44(1): 55-62, 2003

Hormone replacement therapy with transdermal estradiol gel and oral progesterone: Effects on menopausal symptoms and lipid metabolism. Wiener Klinische Wochenschrift 112(14): 629-633, 28 Juli, 2000

Pilot study of hormone replacement therapy and menopausal symptoms, depression, and quality of life in Korean climacteric women. Psychological Reports 98(2): 374-378, 2006

Effects of quarterly hormone replacement therapy on climacteric symptoms, endometrial safety, and lipoproteins. Paoletti, R, Crosignani, P G, Kenemans, P, Soma, M, Jackson, A S Women's health and menopause: Risk reduction strategies 247-251, 1997

Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. Bjog 107(3): 356-364, 2000

Self-adjusted postmenopausal hormone replacement therapy: effects on the biological and immunological profile of FSH and correlation to climacteric symptoms. European Journal of Endocrinology 146(3): 333-338, 2002

Effects of cyclic continuous and sequential post-menopausal hormone replacement therapy on uterine bleeding and climacteric symptoms. Human Reproduction 14(ABSTR BOOK 1): 246, 1999

Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric 13(2): 147-156, 2010

Effects of the hormone replacement therapy on cardiovascular system, bone mass and memory in climacteric patients. Ginecologia Y Obstetricia de Mexico 72(1): 16-22, 2004

Comparison of the effects of oral and transdermal estradiol administration on estrogen metabolism protein synthesis gonadotropin release bone turnover and climacteric symptoms in postmenopausal women. Clinical Endocrinology 30(3): 241-250, 1989

Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism. Wiener Klinische Wochenschrift 112(14): 629-633, 2000

Usefulness of the relationship between follicular stimulating hormone, deoxypyridinoline, estradiol, and inhibin as decision criterion for starting replacement hormone therapy in climacteric and its correlation with symptomatology. Ginecologia Y Obstetricia de Mexico 68: 242-248, 2000